nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Irinotecan—stomach cancer	0.451	1	CbGbCtD
Dolutegravir—POU2F2—hematopoietic system—stomach cancer	0.0247	0.34	CbGeAlD
Dolutegravir—UGT1A1—Heme degradation—BLVRB—stomach cancer	0.0217	0.0962	CbGpPWpGaD
Dolutegravir—POU2F2—lymphoid tissue—stomach cancer	0.0174	0.239	CbGeAlD
Dolutegravir—POU2F2—Ectoderm Differentiation—TFAP2C—stomach cancer	0.0162	0.0715	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CTNNA2—stomach cancer	0.0162	0.0715	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—stomach cancer	0.0126	0.0558	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—GLI3—stomach cancer	0.0122	0.0542	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MALT1—stomach cancer	0.0107	0.0472	CbGpPWpGaD
Dolutegravir—POU2F2—lymph node—stomach cancer	0.00983	0.135	CbGeAlD
Dolutegravir—UGT1A1—Porphyrin metabolism—BLVRB—stomach cancer	0.00945	0.0418	CbGpPWpGaD
Dolutegravir—UGT1A1—hematopoietic system—stomach cancer	0.00747	0.103	CbGeAlD
Dolutegravir—Rash maculo-papular—Floxuridine—stomach cancer	0.00717	0.0286	CcSEcCtD
Dolutegravir—UGT1A1—Heme degradation—HMOX1—stomach cancer	0.00631	0.0279	CbGpPWpGaD
Dolutegravir—Bilirubin total increased—Epirubicin—stomach cancer	0.00625	0.0249	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—RORA—stomach cancer	0.00622	0.0275	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—RUNX3—stomach cancer	0.00608	0.0269	CbGpPWpGaD
Dolutegravir—Bilirubin total increased—Doxorubicin—stomach cancer	0.00578	0.0231	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HSPD1—stomach cancer	0.00572	0.0253	CbGpPWpGaD
Dolutegravir—UGT1A1—digestive system—stomach cancer	0.00519	0.0713	CbGeAlD
Dolutegravir—POU2F2—Ectoderm Differentiation—PAX6—stomach cancer	0.00495	0.0219	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—PPP2R4—stomach cancer	0.00484	0.0214	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—stomach cancer	0.00473	0.0209	CbGpPWpGaD
Dolutegravir—Renal impairment—Mitomycin—stomach cancer	0.00472	0.0188	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HTR1A—stomach cancer	0.00449	0.0199	CbGpPWpGaD
Dolutegravir—Rash macular—Capecitabine—stomach cancer	0.00439	0.0175	CcSEcCtD
Dolutegravir—Rash generalised—Docetaxel—stomach cancer	0.00437	0.0174	CcSEcCtD
Dolutegravir—Serum creatinine increased—Irinotecan—stomach cancer	0.00437	0.0174	CcSEcCtD
Dolutegravir—UGT1A1—endocrine gland—stomach cancer	0.00429	0.0589	CbGeAlD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL1RN—stomach cancer	0.0042	0.0186	CbGpPWpGaD
Dolutegravir—Prurigo—Docetaxel—stomach cancer	0.00403	0.0161	CcSEcCtD
Dolutegravir—Prurigo—Capecitabine—stomach cancer	0.0039	0.0155	CcSEcCtD
Dolutegravir—UGT1A1—liver—stomach cancer	0.00387	0.0531	CbGeAlD
Dolutegravir—POU2F2—Ectoderm Differentiation—SMAD4—stomach cancer	0.00341	0.0151	CbGpPWpGaD
Dolutegravir—Renal failure—Mitomycin—stomach cancer	0.0034	0.0136	CcSEcCtD
Dolutegravir—Opportunistic infection—Methotrexate—stomach cancer	0.00333	0.0133	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SERPINB2—stomach cancer	0.00331	0.0147	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—FYN—stomach cancer	0.00324	0.0143	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—BDNF—stomach cancer	0.00315	0.0139	CbGpPWpGaD
Dolutegravir—Opportunistic infection—Epirubicin—stomach cancer	0.00311	0.0124	CcSEcCtD
Dolutegravir—POU2F2—Ectoderm Differentiation—FGFR2—stomach cancer	0.00304	0.0135	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL10—stomach cancer	0.003	0.0133	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—JUN—stomach cancer	0.003	0.0133	CbGpPWpGaD
Dolutegravir—Serum creatinine increased—Capecitabine—stomach cancer	0.00293	0.0117	CcSEcCtD
Dolutegravir—Opportunistic infection—Doxorubicin—stomach cancer	0.00288	0.0115	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Irinotecan—stomach cancer	0.00284	0.0113	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK8—stomach cancer	0.00284	0.0126	CbGpPWpGaD
Dolutegravir—Nervous system disorder—Floxuridine—stomach cancer	0.00276	0.011	CcSEcCtD
Dolutegravir—UGT1A1—Porphyrin metabolism—HMOX1—stomach cancer	0.00274	0.0121	CbGpPWpGaD
Dolutegravir—Inflammation—Fluorouracil—stomach cancer	0.00265	0.0106	CcSEcCtD
Dolutegravir—Myositis—Epirubicin—stomach cancer	0.00256	0.0102	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK3—stomach cancer	0.00248	0.011	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTM1—stomach cancer	0.00244	0.0108	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP2A6—stomach cancer	0.00239	0.0106	CbGpPWpGaD
Dolutegravir—Myositis—Doxorubicin—stomach cancer	0.00236	0.00944	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK1—stomach cancer	0.00236	0.0104	CbGpPWpGaD
Dolutegravir—Rash maculo-papular—Fluorouracil—stomach cancer	0.00234	0.00934	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Floxuridine—stomach cancer	0.0023	0.00918	CcSEcCtD
Dolutegravir—Abdominal pain—Floxuridine—stomach cancer	0.00222	0.00888	CcSEcCtD
Dolutegravir—UGT1A1—Irinotecan Pathway—APC—stomach cancer	0.00222	0.00981	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—AHR—stomach cancer	0.00213	0.00945	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Floxuridine—stomach cancer	0.00207	0.00827	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6R—stomach cancer	0.00207	0.00916	CbGpPWpGaD
Dolutegravir—Renal impairment—Irinotecan—stomach cancer	0.00205	0.00818	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—stomach cancer	0.00205	0.00906	CbGpPWpGaD
Dolutegravir—Serum creatinine increased—Epirubicin—stomach cancer	0.00204	0.00813	CcSEcCtD
Dolutegravir—Asthenia—Floxuridine—stomach cancer	0.00202	0.00806	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Docetaxel—stomach cancer	0.00196	0.00784	CcSEcCtD
Dolutegravir—Diarrhoea—Floxuridine—stomach cancer	0.00193	0.00768	CcSEcCtD
Dolutegravir—Inflammation—Docetaxel—stomach cancer	0.00192	0.00764	CcSEcCtD
Dolutegravir—Fatigue—Mitomycin—stomach cancer	0.0019	0.0076	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Capecitabine—stomach cancer	0.0019	0.00759	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—stomach cancer	0.00189	0.00839	CbGpPWpGaD
Dolutegravir—Serum creatinine increased—Doxorubicin—stomach cancer	0.00189	0.00752	CcSEcCtD
Dolutegravir—Inflammation—Capecitabine—stomach cancer	0.00185	0.0074	CcSEcCtD
Dolutegravir—Blood creatinine increased—Irinotecan—stomach cancer	0.00183	0.00729	CcSEcCtD
Dolutegravir—Vomiting—Floxuridine—stomach cancer	0.00179	0.00714	CcSEcCtD
Dolutegravir—Rash—Floxuridine—stomach cancer	0.00177	0.00708	CcSEcCtD
Dolutegravir—Dermatitis—Floxuridine—stomach cancer	0.00177	0.00707	CcSEcCtD
Dolutegravir—Headache—Floxuridine—stomach cancer	0.00176	0.00703	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—BLVRB—stomach cancer	0.00169	0.00748	CbGpPWpGaD
Dolutegravir—Nausea—Floxuridine—stomach cancer	0.00167	0.00667	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CXCL8—stomach cancer	0.00164	0.00727	CbGpPWpGaD
Dolutegravir—Asthenia—Mitomycin—stomach cancer	0.00158	0.00632	CcSEcCtD
Dolutegravir—Neutropenia—Irinotecan—stomach cancer	0.00158	0.00629	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL1B—stomach cancer	0.00158	0.00697	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—JUN—stomach cancer	0.00153	0.00676	CbGpPWpGaD
Dolutegravir—Diarrhoea—Mitomycin—stomach cancer	0.00151	0.00603	CcSEcCtD
Dolutegravir—Renal failure—Irinotecan—stomach cancer	0.00148	0.0059	CcSEcCtD
Dolutegravir—Dizziness—Mitomycin—stomach cancer	0.00146	0.00583	CcSEcCtD
Dolutegravir—Renal impairment—Docetaxel—stomach cancer	0.00142	0.00566	CcSEcCtD
Dolutegravir—Vomiting—Mitomycin—stomach cancer	0.0014	0.0056	CcSEcCtD
Dolutegravir—Rash—Mitomycin—stomach cancer	0.00139	0.00556	CcSEcCtD
Dolutegravir—Dermatitis—Mitomycin—stomach cancer	0.00139	0.00555	CcSEcCtD
Dolutegravir—Headache—Mitomycin—stomach cancer	0.00138	0.00552	CcSEcCtD
Dolutegravir—Inflammation—Methotrexate—stomach cancer	0.00138	0.00551	CcSEcCtD
Dolutegravir—Renal impairment—Capecitabine—stomach cancer	0.00137	0.00548	CcSEcCtD
Dolutegravir—POU2F2—Ectoderm Differentiation—MYC—stomach cancer	0.00135	0.00599	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—stomach cancer	0.00133	0.0059	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Epirubicin—stomach cancer	0.00133	0.00529	CcSEcCtD
Dolutegravir—Nausea—Mitomycin—stomach cancer	0.00131	0.00523	CcSEcCtD
Dolutegravir—Inflammation—Epirubicin—stomach cancer	0.00129	0.00516	CcSEcCtD
Dolutegravir—Abnormal dreams—Epirubicin—stomach cancer	0.00124	0.00494	CcSEcCtD
Dolutegravir—Abdominal pain upper—Docetaxel—stomach cancer	0.00123	0.00492	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Doxorubicin—stomach cancer	0.00123	0.00489	CcSEcCtD
Dolutegravir—Blood creatinine increased—Capecitabine—stomach cancer	0.00122	0.00488	CcSEcCtD
Dolutegravir—Immune system disorder—Irinotecan—stomach cancer	0.00122	0.00487	CcSEcCtD
Dolutegravir—Inflammation—Doxorubicin—stomach cancer	0.0012	0.00477	CcSEcCtD
Dolutegravir—Abdominal pain upper—Capecitabine—stomach cancer	0.00119	0.00476	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Docetaxel—stomach cancer	0.00119	0.00475	CcSEcCtD
Dolutegravir—Flatulence—Irinotecan—stomach cancer	0.00116	0.00462	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Capecitabine—stomach cancer	0.00115	0.0046	CcSEcCtD
Dolutegravir—Abnormal dreams—Doxorubicin—stomach cancer	0.00115	0.00457	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TNF—stomach cancer	0.00114	0.00506	CbGpPWpGaD
Dolutegravir—Rash maculo-papular—Epirubicin—stomach cancer	0.00114	0.00455	CcSEcCtD
Dolutegravir—Neutropenia—Docetaxel—stomach cancer	0.00109	0.00435	CcSEcCtD
Dolutegravir—Abdominal discomfort—Capecitabine—stomach cancer	0.00108	0.00432	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTT1—stomach cancer	0.00108	0.00477	CbGpPWpGaD
Dolutegravir—Vertigo—Irinotecan—stomach cancer	0.00106	0.00421	CcSEcCtD
Dolutegravir—Neutropenia—Capecitabine—stomach cancer	0.00106	0.00421	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—stomach cancer	0.00105	0.00421	CcSEcCtD
Dolutegravir—Renal failure—Docetaxel—stomach cancer	0.00102	0.00408	CcSEcCtD
Dolutegravir—Hyperglycaemia—Capecitabine—stomach cancer	0.00102	0.00406	CcSEcCtD
Dolutegravir—Renal failure—Capecitabine—stomach cancer	0.000989	0.00395	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Docetaxel—stomach cancer	0.000983	0.00392	CcSEcCtD
Dolutegravir—Renal impairment—Epirubicin—stomach cancer	0.000956	0.00381	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Capecitabine—stomach cancer	0.000952	0.0038	CcSEcCtD
Dolutegravir—Nervous system disorder—Irinotecan—stomach cancer	0.000941	0.00375	CcSEcCtD
Dolutegravir—Hepatitis—Docetaxel—stomach cancer	0.000933	0.00372	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6—stomach cancer	0.000922	0.00408	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Docetaxel—stomach cancer	0.000922	0.00368	CcSEcCtD
Dolutegravir—Urethral disorder—Docetaxel—stomach cancer	0.000915	0.00365	CcSEcCtD
Dolutegravir—Hepatitis—Capecitabine—stomach cancer	0.000904	0.0036	CcSEcCtD
Dolutegravir—Nervous system disorder—Fluorouracil—stomach cancer	0.000901	0.00359	CcSEcCtD
Dolutegravir—Urinary tract disorder—Capecitabine—stomach cancer	0.000892	0.00356	CcSEcCtD
Dolutegravir—Urethral disorder—Capecitabine—stomach cancer	0.000886	0.00353	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—stomach cancer	0.000885	0.00353	CcSEcCtD
Dolutegravir—Insomnia—Irinotecan—stomach cancer	0.000868	0.00346	CcSEcCtD
Dolutegravir—Blood creatinine increased—Epirubicin—stomach cancer	0.000852	0.0034	CcSEcCtD
Dolutegravir—Immune system disorder—Docetaxel—stomach cancer	0.000843	0.00336	CcSEcCtD
Dolutegravir—Abdominal pain upper—Epirubicin—stomach cancer	0.000831	0.00332	CcSEcCtD
Dolutegravir—Insomnia—Fluorouracil—stomach cancer	0.000831	0.00331	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Irinotecan—stomach cancer	0.000828	0.0033	CcSEcCtD
Dolutegravir—Fatigue—Irinotecan—stomach cancer	0.000827	0.0033	CcSEcCtD
Dolutegravir—Mental disorder—Docetaxel—stomach cancer	0.000818	0.00326	CcSEcCtD
Dolutegravir—Immune system disorder—Capecitabine—stomach cancer	0.000816	0.00326	CcSEcCtD
Dolutegravir—Abdominal discomfort—Methotrexate—stomach cancer	0.000806	0.00321	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Epirubicin—stomach cancer	0.000803	0.0032	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.000793	0.00316	CcSEcCtD
Dolutegravir—Mental disorder—Capecitabine—stomach cancer	0.000792	0.00316	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—stomach cancer	0.000789	0.00315	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFA—stomach cancer	0.000788	0.00349	CbGpPWpGaD
Dolutegravir—Neutropenia—Methotrexate—stomach cancer	0.000786	0.00314	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Irinotecan—stomach cancer	0.000784	0.00313	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SERPINA1—stomach cancer	0.000776	0.00344	CbGpPWpGaD
Dolutegravir—Flatulence—Capecitabine—stomach cancer	0.000775	0.00309	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—stomach cancer	0.000769	0.00307	CcSEcCtD
Dolutegravir—Abdominal pain—Irinotecan—stomach cancer	0.000758	0.00303	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTP1—stomach cancer	0.000747	0.0033	CbGpPWpGaD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—stomach cancer	0.000743	0.00296	CcSEcCtD
Dolutegravir—Renal failure—Methotrexate—stomach cancer	0.000737	0.00294	CcSEcCtD
Dolutegravir—Neutropenia—Epirubicin—stomach cancer	0.000735	0.00293	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—CYP2A6—stomach cancer	0.00071	0.00314	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Epirubicin—stomach cancer	0.000709	0.00283	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Methotrexate—stomach cancer	0.000709	0.00283	CcSEcCtD
Dolutegravir—Vertigo—Capecitabine—stomach cancer	0.000707	0.00282	CcSEcCtD
Dolutegravir—Hypersensitivity—Irinotecan—stomach cancer	0.000707	0.00282	CcSEcCtD
Dolutegravir—Renal failure—Epirubicin—stomach cancer	0.000689	0.00275	CcSEcCtD
Dolutegravir—Asthenia—Irinotecan—stomach cancer	0.000688	0.00275	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.000687	0.00274	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM1—stomach cancer	0.000686	0.00304	CbGpPWpGaD
Dolutegravir—Neutropenia—Doxorubicin—stomach cancer	0.00068	0.00271	CcSEcCtD
Dolutegravir—Hypersensitivity—Fluorouracil—stomach cancer	0.000677	0.0027	CcSEcCtD
Dolutegravir—Hepatitis—Methotrexate—stomach cancer	0.000673	0.00268	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.000665	0.00265	CcSEcCtD
Dolutegravir—Urinary tract disorder—Methotrexate—stomach cancer	0.000664	0.00265	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Epirubicin—stomach cancer	0.000663	0.00265	CcSEcCtD
Dolutegravir—Urethral disorder—Methotrexate—stomach cancer	0.000659	0.00263	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—stomach cancer	0.000656	0.00262	CcSEcCtD
Dolutegravir—Diarrhoea—Irinotecan—stomach cancer	0.000656	0.00262	CcSEcCtD
Dolutegravir—Nervous system disorder—Docetaxel—stomach cancer	0.00065	0.00259	CcSEcCtD
Dolutegravir—Pruritus—Fluorouracil—stomach cancer	0.00065	0.00259	CcSEcCtD
Dolutegravir—Skin disorder—Docetaxel—stomach cancer	0.000644	0.00257	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—stomach cancer	0.000638	0.00254	CcSEcCtD
Dolutegravir—Dizziness—Irinotecan—stomach cancer	0.000634	0.00253	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTT1—stomach cancer	0.00063	0.00279	CbGpPWpGaD
Dolutegravir—Nervous system disorder—Capecitabine—stomach cancer	0.00063	0.00251	CcSEcCtD
Dolutegravir—Hepatitis—Epirubicin—stomach cancer	0.000629	0.00251	CcSEcCtD
Dolutegravir—Diarrhoea—Fluorouracil—stomach cancer	0.000629	0.00251	CcSEcCtD
Dolutegravir—Skin disorder—Capecitabine—stomach cancer	0.000624	0.00249	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP2A6—stomach cancer	0.000623	0.00276	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Epirubicin—stomach cancer	0.000622	0.00248	CcSEcCtD
Dolutegravir—Urethral disorder—Epirubicin—stomach cancer	0.000617	0.00246	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—stomach cancer	0.000616	0.00272	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Doxorubicin—stomach cancer	0.000614	0.00245	CcSEcCtD
Dolutegravir—Vomiting—Irinotecan—stomach cancer	0.00061	0.00243	CcSEcCtD
Dolutegravir—Immune system disorder—Methotrexate—stomach cancer	0.000608	0.00242	CcSEcCtD
Dolutegravir—Dizziness—Fluorouracil—stomach cancer	0.000607	0.00242	CcSEcCtD
Dolutegravir—Rash—Irinotecan—stomach cancer	0.000605	0.00241	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—stomach cancer	0.000605	0.00268	CbGpPWpGaD
Dolutegravir—Dermatitis—Irinotecan—stomach cancer	0.000604	0.00241	CcSEcCtD
Dolutegravir—Headache—Irinotecan—stomach cancer	0.000601	0.0024	CcSEcCtD
Dolutegravir—Insomnia—Docetaxel—stomach cancer	0.0006	0.00239	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—AKR1C3—stomach cancer	0.000598	0.00264	CbGpPWpGaD
Dolutegravir—Mental disorder—Methotrexate—stomach cancer	0.000589	0.00235	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—stomach cancer	0.000586	0.00259	CbGpPWpGaD
Dolutegravir—Vomiting—Fluorouracil—stomach cancer	0.000584	0.00233	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—stomach cancer	0.000582	0.00232	CcSEcCtD
Dolutegravir—Insomnia—Capecitabine—stomach cancer	0.000581	0.00232	CcSEcCtD
Dolutegravir—Rash—Fluorouracil—stomach cancer	0.000579	0.00231	CcSEcCtD
Dolutegravir—Dermatitis—Fluorouracil—stomach cancer	0.000579	0.00231	CcSEcCtD
Dolutegravir—Headache—Fluorouracil—stomach cancer	0.000575	0.0023	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—stomach cancer	0.000575	0.00229	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000572	0.00228	CcSEcCtD
Dolutegravir—Fatigue—Docetaxel—stomach cancer	0.000572	0.00228	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—stomach cancer	0.000571	0.00228	CcSEcCtD
Dolutegravir—Nausea—Irinotecan—stomach cancer	0.00057	0.00227	CcSEcCtD
Dolutegravir—Immune system disorder—Epirubicin—stomach cancer	0.000569	0.00227	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—HBEGF—stomach cancer	0.000561	0.00248	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000554	0.00221	CcSEcCtD
Dolutegravir—Fatigue—Capecitabine—stomach cancer	0.000553	0.00221	CcSEcCtD
Dolutegravir—Mental disorder—Epirubicin—stomach cancer	0.000551	0.0022	CcSEcCtD
Dolutegravir—Nausea—Fluorouracil—stomach cancer	0.000546	0.00218	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Docetaxel—stomach cancer	0.000542	0.00216	CcSEcCtD
Dolutegravir—Flatulence—Epirubicin—stomach cancer	0.00054	0.00215	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—stomach cancer	0.000526	0.0021	CcSEcCtD
Dolutegravir—Vertigo—Methotrexate—stomach cancer	0.000526	0.0021	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Capecitabine—stomach cancer	0.000525	0.00209	CcSEcCtD
Dolutegravir—Abdominal pain—Docetaxel—stomach cancer	0.000524	0.00209	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—stomach cancer	0.00051	0.00204	CcSEcCtD
Dolutegravir—Abdominal pain—Capecitabine—stomach cancer	0.000507	0.00202	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—stomach cancer	0.0005	0.00199	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTP1—stomach cancer	0.000498	0.0022	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000495	0.00198	CcSEcCtD
Dolutegravir—Vertigo—Epirubicin—stomach cancer	0.000492	0.00196	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—HMOX1—stomach cancer	0.000491	0.00217	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Docetaxel—stomach cancer	0.000488	0.00195	CcSEcCtD
Dolutegravir—Asthenia—Docetaxel—stomach cancer	0.000476	0.0019	CcSEcCtD
Dolutegravir—Hypersensitivity—Capecitabine—stomach cancer	0.000473	0.00189	CcSEcCtD
Dolutegravir—Pruritus—Docetaxel—stomach cancer	0.000469	0.00187	CcSEcCtD
Dolutegravir—Nervous system disorder—Methotrexate—stomach cancer	0.000469	0.00187	CcSEcCtD
Dolutegravir—Skin disorder—Methotrexate—stomach cancer	0.000464	0.00185	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000463	0.00185	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—stomach cancer	0.000461	0.00204	CbGpPWpGaD
Dolutegravir—Asthenia—Capecitabine—stomach cancer	0.000461	0.00184	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM1—stomach cancer	0.000458	0.00203	CbGpPWpGaD
Dolutegravir—Vertigo—Doxorubicin—stomach cancer	0.000456	0.00182	CcSEcCtD
Dolutegravir—Pruritus—Capecitabine—stomach cancer	0.000454	0.00181	CcSEcCtD
Dolutegravir—Diarrhoea—Docetaxel—stomach cancer	0.000454	0.00181	CcSEcCtD
Dolutegravir—Diarrhoea—Capecitabine—stomach cancer	0.000439	0.00175	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—stomach cancer	0.000439	0.00194	CbGpPWpGaD
Dolutegravir—Nervous system disorder—Epirubicin—stomach cancer	0.000439	0.00175	CcSEcCtD
Dolutegravir—Dizziness—Docetaxel—stomach cancer	0.000438	0.00175	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTP1—stomach cancer	0.000437	0.00193	CbGpPWpGaD
Dolutegravir—Skin disorder—Epirubicin—stomach cancer	0.000434	0.00173	CcSEcCtD
Dolutegravir—Insomnia—Methotrexate—stomach cancer	0.000432	0.00172	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTP1—stomach cancer	0.000431	0.00191	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000429	0.00171	CcSEcCtD
Dolutegravir—Dizziness—Capecitabine—stomach cancer	0.000424	0.00169	CcSEcCtD
Dolutegravir—Vomiting—Docetaxel—stomach cancer	0.000422	0.00168	CcSEcCtD
Dolutegravir—Rash—Docetaxel—stomach cancer	0.000418	0.00167	CcSEcCtD
Dolutegravir—Dermatitis—Docetaxel—stomach cancer	0.000418	0.00167	CcSEcCtD
Dolutegravir—Headache—Docetaxel—stomach cancer	0.000415	0.00166	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000413	0.00165	CcSEcCtD
Dolutegravir—Fatigue—Methotrexate—stomach cancer	0.000412	0.00164	CcSEcCtD
Dolutegravir—Vomiting—Capecitabine—stomach cancer	0.000408	0.00163	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—stomach cancer	0.000406	0.00162	CcSEcCtD
Dolutegravir—Rash—Capecitabine—stomach cancer	0.000405	0.00161	CcSEcCtD
Dolutegravir—Insomnia—Epirubicin—stomach cancer	0.000404	0.00161	CcSEcCtD
Dolutegravir—Dermatitis—Capecitabine—stomach cancer	0.000404	0.00161	CcSEcCtD
Dolutegravir—Headache—Capecitabine—stomach cancer	0.000402	0.0016	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—stomach cancer	0.000402	0.0016	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTM1—stomach cancer	0.000401	0.00178	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM1—stomach cancer	0.000396	0.00175	CbGpPWpGaD
Dolutegravir—Nausea—Docetaxel—stomach cancer	0.000394	0.00157	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Methotrexate—stomach cancer	0.000391	0.00156	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000386	0.00154	CcSEcCtD
Dolutegravir—Fatigue—Epirubicin—stomach cancer	0.000386	0.00154	CcSEcCtD
Dolutegravir—Nausea—Capecitabine—stomach cancer	0.000381	0.00152	CcSEcCtD
Dolutegravir—Abdominal pain—Methotrexate—stomach cancer	0.000378	0.00151	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ACAD8—stomach cancer	0.000375	0.00166	CbGpPWpGaD
Dolutegravir—Insomnia—Doxorubicin—stomach cancer	0.000374	0.00149	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Epirubicin—stomach cancer	0.000366	0.00146	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000357	0.00143	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—stomach cancer	0.000357	0.00142	CcSEcCtD
Dolutegravir—Abdominal pain—Epirubicin—stomach cancer	0.000354	0.00141	CcSEcCtD
Dolutegravir—Hypersensitivity—Methotrexate—stomach cancer	0.000352	0.0014	CcSEcCtD
Dolutegravir—Asthenia—Methotrexate—stomach cancer	0.000343	0.00137	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000338	0.00135	CcSEcCtD
Dolutegravir—Pruritus—Methotrexate—stomach cancer	0.000338	0.00135	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—GMPR2—stomach cancer	0.000335	0.00148	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Epirubicin—stomach cancer	0.000329	0.00131	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—stomach cancer	0.000327	0.00131	CcSEcCtD
Dolutegravir—Diarrhoea—Methotrexate—stomach cancer	0.000327	0.0013	CcSEcCtD
Dolutegravir—Asthenia—Epirubicin—stomach cancer	0.000321	0.00128	CcSEcCtD
Dolutegravir—Pruritus—Epirubicin—stomach cancer	0.000316	0.00126	CcSEcCtD
Dolutegravir—Dizziness—Methotrexate—stomach cancer	0.000316	0.00126	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—SUCLG1—stomach cancer	0.000306	0.00135	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—IDH3B—stomach cancer	0.000306	0.00135	CbGpPWpGaD
Dolutegravir—Diarrhoea—Epirubicin—stomach cancer	0.000306	0.00122	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—stomach cancer	0.000305	0.00122	CcSEcCtD
Dolutegravir—Vomiting—Methotrexate—stomach cancer	0.000304	0.00121	CcSEcCtD
Dolutegravir—Rash—Methotrexate—stomach cancer	0.000301	0.0012	CcSEcCtD
Dolutegravir—Dermatitis—Methotrexate—stomach cancer	0.000301	0.0012	CcSEcCtD
Dolutegravir—Headache—Methotrexate—stomach cancer	0.000299	0.00119	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—stomach cancer	0.000297	0.00118	CcSEcCtD
Dolutegravir—Dizziness—Epirubicin—stomach cancer	0.000296	0.00118	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—stomach cancer	0.000293	0.00117	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—NDUFV1—stomach cancer	0.000285	0.00126	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NDUFS1—stomach cancer	0.000285	0.00126	CbGpPWpGaD
Dolutegravir—Vomiting—Epirubicin—stomach cancer	0.000284	0.00113	CcSEcCtD
Dolutegravir—Nausea—Methotrexate—stomach cancer	0.000284	0.00113	CcSEcCtD
Dolutegravir—Diarrhoea—Doxorubicin—stomach cancer	0.000283	0.00113	CcSEcCtD
Dolutegravir—Rash—Epirubicin—stomach cancer	0.000282	0.00113	CcSEcCtD
Dolutegravir—Dermatitis—Epirubicin—stomach cancer	0.000282	0.00112	CcSEcCtD
Dolutegravir—Headache—Epirubicin—stomach cancer	0.00028	0.00112	CcSEcCtD
Dolutegravir—Dizziness—Doxorubicin—stomach cancer	0.000274	0.00109	CcSEcCtD
Dolutegravir—Nausea—Epirubicin—stomach cancer	0.000266	0.00106	CcSEcCtD
Dolutegravir—Vomiting—Doxorubicin—stomach cancer	0.000263	0.00105	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—stomach cancer	0.000261	0.00104	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—stomach cancer	0.000261	0.00104	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—stomach cancer	0.000259	0.00103	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—BLVRB—stomach cancer	0.000254	0.00112	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PGLS—stomach cancer	0.000254	0.00112	CbGpPWpGaD
Dolutegravir—Nausea—Doxorubicin—stomach cancer	0.000246	0.000981	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—PPAP2A—stomach cancer	0.000242	0.00107	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CA1—stomach cancer	0.000216	0.000954	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CKB—stomach cancer	0.000216	0.000954	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NDUFA2—stomach cancer	0.000216	0.000954	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—FBP1—stomach cancer	0.000216	0.000954	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PLIN2—stomach cancer	0.000203	0.000897	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CA2—stomach cancer	0.000197	0.000873	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PGAM1—stomach cancer	0.000192	0.000851	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NT5E—stomach cancer	0.000192	0.000851	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PLCE1—stomach cancer	0.000183	0.000812	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALDH7A1—stomach cancer	0.000183	0.000812	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—UMPS—stomach cancer	0.000176	0.000778	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PDHA1—stomach cancer	0.000163	0.000723	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ECHS1—stomach cancer	0.000163	0.000723	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TYMP—stomach cancer	0.000154	0.00068	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—FADS1—stomach cancer	0.000154	0.00068	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SREBF2—stomach cancer	0.000144	0.000637	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—RORA—stomach cancer	0.000142	0.000629	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALDOB—stomach cancer	0.000133	0.00059	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALOX5—stomach cancer	0.000124	0.000548	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—DPYD—stomach cancer	0.000122	0.000539	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTT1—stomach cancer	0.000108	0.000477	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP2A6—stomach cancer	0.000107	0.000471	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKR1C3—stomach cancer	0.000104	0.000459	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ENO1—stomach cancer	0.000101	0.000447	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CD44—stomach cancer	8.96e-05	0.000396	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PPP2R1A—stomach cancer	7.61e-05	0.000337	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTP1—stomach cancer	7.47e-05	0.000331	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HMOX1—stomach cancer	7.37e-05	0.000326	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TYMS—stomach cancer	6.94e-05	0.000307	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM1—stomach cancer	6.86e-05	0.000304	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ERCC2—stomach cancer	6.45e-05	0.000286	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTHFR—stomach cancer	6.07e-05	0.000268	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CAV1—stomach cancer	5.6e-05	0.000248	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—APOA1—stomach cancer	5.58e-05	0.000247	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PPARG—stomach cancer	4.92e-05	0.000218	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALB—stomach cancer	4.42e-05	0.000196	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NOS3—stomach cancer	4.23e-05	0.000187	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—stomach cancer	3.87e-05	0.000171	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—stomach cancer	2.38e-05	0.000105	CbGpPWpGaD
